血管质量倡议胸主动脉腔内修复治疗夹层上市后项目中逆行A型夹层的分析
本研究基于血管质量倡议胸主动脉腔内修复治疗夹层注册项目,纳入49家机构588例连续行胸主动脉腔内修复(TEVAR)的B型主动脉夹层患者(急性<30天336例,慢性≥30天252例),评估逆行夹层(RD)及逆行A型夹层(RTAD)的发生率与危险因素。与RTAD相关的因素包括夹层范围更广泛、女性及非白种人趋势。
要点
- RTAD患者总体死亡率为33.3%(5/15)。
- 夹层范围更广泛与RTAD相关(无RTAD平均5.6个分区 vs 有RTAD平均8.5个分区,P=0.001)。
核心结论
- 本真实世界上市后项目中RD发生率与既往研究(包括高度对照的关键性研究)一致。
- 装置类型不能预测RD,新发现的RTAD危险因素包括更广泛的夹层以及女性和非白种人风险增加的趋势。
研究设计与样本
- 血管质量倡议TEVAR治疗夹层注册项目为前瞻性收集的真实世界注册研究,旨在满足美国食品药品监督管理局对Gore conformable TAG胸主动脉内假体、Medtronic Valiant胸主动脉覆膜支架和Cook Medical夹层装置的上市后批准监测要求。
- 共纳入49家机构588例连续接受TEVAR的B型主动脉夹层患者,其中急性(<30天)336例,慢性(≥30天)252例。
- RD的发生由参与中心报告,并由两名研究者(A.W.B.和G.W.)独立审阅去标识化源文件确认。
- 装置以去标识化方式分组为Gore、Medtronic和其他。
主要发现
- 平均随访889天(中位数658天),408例患者有超过1年的完整随访数据。
- 共识别19例RD(3.2%),其中急性夹层治疗9例(2.7%),慢性夹层治疗10例(4.0%),急性与慢性比较P=0.48。
- 19例RD中15例为RTAD,其中急性夹层治疗后6例(1.8%),慢性夹层治疗后9例(3.6%),急性与慢性比较P=0.19。
- 5例RD发生在术中(其中4例为RTAD);RD和RTAD的中位发生时间分别为62天和69天(范围0至1600天)。
- 15例RTAD中,12例接受外科修复,2例未接受修复,1例治疗未知;总体死亡率为33.3%(5/15)。
关键数值与推荐
- 急性与慢性B型夹层TEVAR后RD发生率分别为2.7%和4.0%(P=0.48)。
- 急性与慢性B型夹层TEVAR后RTAD发生率分别为1.8%和3.6%(P=0.19)。
- RTAD总体死亡率为33.3%(5/15)。
- 无RTAD与有RTAD患者平均 oversizing 分别为14.0%和14.2%(P=0.92)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retrograde dissection (RD) can be a serious complication after thoracic endovascular aortic repair (TEVAR), with retrograde type A dissection (RTAD) particularly life-threatening. Prior studies have suggested that treatment timing, anatomic characteristics, device selection, and procedural conduct of TEVAR performed for type B aortic dissection could mitigate the occurrence of RD. The Vascular Quality Initiative TEVAR for Dissection Registry is an ongoing project meant to satisfy Food and Drug Administration requirements for postmarket approval surveillance of the Gore conformable TAG thoracic endoprosthesis (W.L. Gore & Associates, Flagstaff, Ariz), Medtronic Valiant thoracic stent graft (Medtronic, Santa Rosa, Calif), and Cook Medical dissection devices (Cook Medical, Bloomington, Ind) and provides a unique source of evaluation for RTAD in a prospectively collected real-world registry. METHODS: A total of 588 consecutive patients at 49 institutions had undergone TEVAR for acute (<30 days; n = 336) and chronic (≥30 days; n = 252) type B aortic dissection were included. The occurrence of RD as reported by the participating centers and de-identified source documents were reviewed and confirmed independently by two of us (A.W.B. and G.W.). The demographics, procedural and device data, and anatomic considerations were evaluated, and the devices were grouped in a de-identified manner as Gore, Medtronic, and other. RESULTS: The mean follow-up was 889 days (median, 658 days), and 408 patients had completed follow-up data available for >1 year. A total of 19 patients with RD (3.2%) were identified, 9 of whom had been treated for acute and 10 for chronic dissection, a 2.7% and 4.0% incidence, respectively (P = .48, acute vs chronic). Of the 19 RD cases, 15 were RTAD, 6 after treatment of acute and 9 after treatment of chronic dissection, a 1.8% and 3.6% incidence, respectively (P = .19, acute vs chronic). Five cases of RD had occurred intraoperatively (four of which were RTAD). The median time to RD and RTAD was 62 and 69 days, respectively (range, 0 to 1600 days). Of the 15 patients with RTAD, 12 had undergone surgical repair and 2 had not undergone repair; the treatment of one was unknown. The overall mortality was 33.3% (5 of 15). The factors associated with RTAD included more extensive dissection (mean, 5.6 zones without RTAD vs 8.5 zones with RTAD; P = .001), female sex (28.3% female without RTAD vs 53.3% with RTAD; P = .04), and non-White race (62.7% White without RTAD vs 33.3% White with RTAD; P = .05). Mean oversizing was not significantly different for those without RTAD compared with that for those with RTAD (14.0% vs 14.2%; P = .92). The device type was anonymized in this project; however, we found no significant differences between the Gore, Medtronic, and all other devices. CONCLUSIONS: The rate of RD in the present real-world postapproval project was consistent with that from previously reported studies, including highly controlled pivotal studies. Device type was not predictive of RD, and the newly identified risk factors for RTAD include more extensive dissection and a trend toward a greater risk for female sex and non-White race.
引用
- Beck AW, Wang G, Lombardi JV, et al. Retrograde type A dissection in the Vascular Quality Initiative thoracic endovascular aortic repair for dissection postapproval project. J Vasc Surg. 2022. PMID: 35090993. doi:10.1016/j.jvs.2021.11.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。